Results 101 to 110 of about 3,353 (184)

Clinical imipenem non-susceptible Klebsiella pneumoniae isolates from China: Epidemiology, molecular characterization and in vitro activity of imipenem/relebactam

Journal of Global Antimicrobial Resistance
Objective: To describe the epidemiological and molecular characterization and in vitro activity of imipenem/relebactam against imipenem non-susceptible (IPMNS) Klebsiella pneumoniae isolates in China. Methods: K.
Peiyao Jia, Pengcheng Li, Wei Yu, Xiaobing Chu, Hui Zhang, Jingjia Zhang, Wei Kang, Ge Zhang, Qian Zhang, Shiyu Chen, Yingchun Xu, Qiwen Yang   +11 more
doaj   +1 more source

Combinación de antibióticos carbapenémicos con relebactam sobre enterobacterias productoras de carbapenemasas

Correo Científico Médico
Las enterobacterias productoras de carbapenemasas se han diseminado por todo el mundo y causan infecciones de alta mortalidad y morbilidad. Los antibióticos carbapenémicos se utilizan como último recurso frente a las infecciones graves producidas por ...
Washington Paúl Culqui Molina, Martha Elizabeth Loor Flores, Mónica Viviana Moscoso Silva   +2 more
doaj  

Comparative analysis of in vitro dynamics and mechanisms of ceftolozane/tazobactam and imipenem/relebactam resistance development in Pseudomonas aeruginosa XDR high-risk clones

[eng] Objectives: To analyse the dynamics and mechanisms of stepwise resistance development to ceftolozane/tazobactam and imipenem/relebactam in XDR Pseudomonas aeruginosa clinical strains.
Gomis-Font, María A., López-Argüello, Silvia, Moyá, Bartolomé, Zamorano, Laura, Oliver, Antonio, Cabot, Gabriel, Juan, Carlos   +6 more
core   +1 more source

In vitro, intracellular and in vivo s ynergy between amoxicillin, imipenem and relebactam against Mycobacterium abscessus

International audienceAbstract Objectives : Mycobacterium abscessus is the most frequent of the rapidly growing mycobacteria responsible for lung infections in patients suffering from cystic fibrosis and COPD.
Bitar, Maria, Le Moigne, Vincent, Mainardi, Jean-Luc, Herrmann, Jean-Louis, Arthur, Michel   +4 more
core   +1 more source

Imipenem/cilastatin/relebactam treatment of hospital-acquired/ventilator-associated bacterial pneumonia caused by imipenem-nonsusceptible pathogens: Subgroup analysis and molecular characterization of isolates from the RESTORE-IMI 2 clinical study. [PDF]

PLoS One
Young K, DeRyke CA, Hilbert DW, Losada MC, Du J, Paschke A, Chen LF.   +6 more
europepmc   +1 more source

In Vitro Activity of Imipenem-Funobactam Against Clinical Isolates of Gram-Negative Bacilli. [PDF]

Antibiotics (Basel)
Karlowsky JA, Wise MG, Shi Q, Zhang W, Le M, Li J.   +5 more
europepmc   +1 more source

A Ten-Year Trend of Antimicrobial Resistance in <i>Pseudomonas aeruginosa</i> From United States Medical Centers: Results From the INFORM Surveillance Program (2015-2024). [PDF]

Open Forum Infect Dis
Sader HS, Mendes RE, Lock J, Papp-Wallace KM, Castanheira M.   +4 more
europepmc   +1 more source

Rapid prediction of carbapenemases in by imipenem/relebactam and MALDI-TOF MS

Pseudomonas aeruginosa is a major nosocomial pathogen commonly involved in multidrug-resistant (MDR) infections that are very difficult to treat. Imipenem/relebactam is a new carbapenem/β-lactamase inhibitor combination with robust activity against P. aeruginosa.
Candela, Ana, Fernández-Billón, María, Aja-Macaya, Pablo, González-Pinto, Lucía, Fraile-Ribot, Pablo, Viedma, Esther, Alonso-García, Isaac, Blanco-Martín, Tania, Estévez-Alfaya, Roberto, Fernández-González, Ana, Beceiro, Alejandro, López-Causapé, Carla, Oviaño, Marina, Bou, Germán, Oliver, Antonio, Arca-Suárez, Jorge   +15 more
openaire   +1 more source

<i>In vitro</i> potency of novel ertapenem/zidebactam combination (WCK 6777) against carbapenemase-producing Enterobacterales collected across India. [PDF]

JAC Antimicrob Resist
Bakthavatchalam YD, Bonomo R, Egli A, Puthan R, Shankar A, Krishnamoorthy S, Nagvekar V, Ekadashi RS, J S, Rajan S, Rodrigues C, Jayaprada R, Manesh A, Veeraraghavan B.   +13 more
europepmc   +1 more source

Effect of Imipenem-Relebactam on Sub-types of KPC in Klebsiella pneumoniae [PDF]

Open Forum Infectious Diseases, 2016
Katherine Young, Mary Motyl, Daniel Tatosian   +2 more
openaire   +1 more source